MUC16 and cancer: Within the pre-menopausal cohort, CA125 was significantly elevated in cancers relative to benign cases (stage I vs. benign, p < 0.0001; stages II–IV vs. benign, p < 0.0001) as well as between cancer stages (stage I vs. stages II–IV, p = 0.03).